Evidence map›Paper›PMID 38014499›Full record

ArticleCancer reports (Hoboken, N.J.)2024

Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine.

Shinichi Ogawa, Tatsuhiro Sakamoto, Ryota Matsuoka, Kantaro Ishitsuka, Yasuko Ogino, Ayano Sootome, Kenichi Makishima, Chikashi Yoshida, Yufu Ito, Seiichi Shimizu and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Shinichi OgawaDivision of Hematology, JA Toride General Medical Center, Toride, Ibaraki, Japan.ORCID 0000-0002-7416-0926
Tatsuhiro SakamotoDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Ryota MatsuokaDepartment of Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Kantaro IshitsukaGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Yasuko OginoDivision of Hematology, JA Toride General Medical Center, Toride, Ibaraki, Japan.
Ayano SootomeDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Kenichi MakishimaGraduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Chikashi YoshidaDivision of Hematology, National Hospital Organization Mito Medical Center, Mito, Ibaraki, Japan.
Yufu ItoDivision of Hematology, Tsuchiura Kyoudou General Hospital, Tsuchiura, Ibaraki, Japan.
Seiichi ShimizuDivision of Hematology, Tsuchiura Kyoudou General Hospital, Tsuchiura, Ibaraki, Japan.
Takuya SuyamaDivision of Hematology, Hitachi General Hospital, Hitachi, Ibaraki, Japan.
Atsushi ShinagawaDivision of Hematology, Hitachi General Hospital, Hitachi, Ibaraki, Japan.
Takayoshi ItoDivision of Hematology, JA Toride General Medical Center, Toride, Ibaraki, Japan.
Naoshi ObaraDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Manabu KusakabeDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Mamiko Sakata-YanagimotoDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Yasuhito NannyaDepartment of Hematology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Shigeru ChibaDepartment of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
University of Tsukuba · JPJA Toride Medical Center · JPHitachi General Hospital · JPTsuchiura Kyodo General Hospital · JPNagasaki Institute of Applied Science · JPNational Hospital Organization Mito Medical Center · JPTokyo Medical University · JP

Funding

Japan Agency for Medical Research and Development cm0106505hJapan Society for the Promotion of Science 21K16261
6 · The paper itself

Abstract

backgroundHypomethylating agents, including azacytidine (AZA), are standard therapeutics for patients with high-risk myelodysplastic syndromes (MDS), a group of myeloid neoplasms. However, treatment schedules are not unified in real-world practice; in addition to the standard 7-day (standard-dose) schedule, shortened (reduced-dose) schedules are also used.

aimsThe aim of this study was to discover the patient group(s) which show differential efficacy between standard-and reduced-dose AZA to MDS. METHODS AND

resultsThe outcome of different AZA doses in a cohort of 151 MDS patients were retrospectively analyzed. Overall survival (OS) was not significantly different between standard- and reduced-dose AZA groups by multivariate analysis. However, an interaction was found between either the sex (female vs. male), the platelet counts (< 40 × 10

conclusionWe identified the union of female and preserved platelet count subgroups which benefited from standard-dose AZA, imparting crucial information to physicians planning treatment regimens in MDS patients.

Indexed as

AzacitidineMyelodysplastic SyndromesAntimetabolites, AntineoplasticFemaleHumansMalePlatelet CountRetrospective StudiesTreatment OutcomeAntimetabolites, AntineoplasticAzacitidineazacitidinedosemyelodysplastic syndromeplatelet countssex

Identifiers

PMID38014499
PMCPMC10809187
OpenAlexW4389090979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.